EV/EBITDA Multiple: Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma (MTNB) management effectively allocates capital for research by leveraging automated LNC systems that minimize manual labor during drug dosing. This EV/EBITDA chart shows the current metric at 0.00. Growth prospects are based on a scalable drug delivery system that enables the company to generate profit through licensing royalties from global behemoths without requiring additional capital expenditures.
matinasbiopharma.com (MTNB) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Matinas BioPharma|MTNB - Long-Term Debt to Equity|Short-Term Debt to Equity Matinas BioPharma Holdings|MTNB - Company Cumulative Debt|Debt to Book Capitalization Ratio Matinas BioPharma|MTNB - Company Long-Term Debt|Company Short-Term Debts Matinas BioPharma|Quick Liquidity matinasbiopharma.com
- net income and valuation multiples indicators:
MTNB - Net Financial Result|Expected Profit Matinas BioPharma|MTNB - Price to Earnings Ratio|Future Price to Earnings Matinas BioPharma Holdings|MTNB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Matinas BioPharma|MTNB - Operating profit EBITDA|Net earnings per share for the last 12 months Matinas BioPharma|MTNB - Earnings per share for the last four quarters|Quarterly EPS earnings growth matinasbiopharma.com|MTNB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Matinas BioPharma
Initial company analysis:MTNB (Matinas BioPharma Holdings Inc.)
Matinas BioPharma focuses on the early stages of drug delivery platform development through patent licensing. The enterprise value to EBITDA ratio allows for a business valuation that accounts for net debt while excluding the impact of tax regimes. By analyzing the historical EV/EBITDA multiple of the business, an investor can identify asset undervaluation while avoiding value traps during periods of declining margins.
Who Matinas BioPharma competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences SGMT|BIOA - Enterprise Value to EBITDA Ratio|Biomea Fusion - EV/EBITDA Multiple|QNCX - EV/EBITDA Multiple|GUTS (Fractyl) - Enterprise Value to EBITDA Ratio|VTVT: Enterprise Value to Operating Income Before Depreciation Ratio|ATPC (Agape ATP Corp) - EV/EBITDA Multiple|Pluri Inc (PLUR) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Synlogic, Inc. (SYBX)|Lipocine Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (Spruce Biosciences)|EV/EBITDA Multiple Galecto Corporation GLTO|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|ONVO (Organovo) - Enterprise Value to EBITDA Ratio|Radius Recycling Inc. - Business Value to Operating Income Before Depreciation
